|Bid||66.74 x 1800|
|Ask||66.81 x 900|
|Day's Range||66.39 - 68.00|
|52 Week Range||66.39 - 142.11|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||31.32|
|Earnings Date||May 03, 2021 - May 07, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||117.43|
About 12% of Haemonetics 2020 revenue came from a contract with CSL Plasma. CSL declined to renew the accord.
Haemonetics Corporation (NYSE: HAE) ("Haemonetics" or the "Company"), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that CSL Plasma, Ltd. ("CSL") has informed Haemonetics of its intent not to renew its Supply Agreement with Haemonetics for the use of PCS2® Plasma Collection System devices and the purchase of disposable plasmapheresis kits in the U.S. following the expiration of the current term in June 2022. Haemonetics was informed that the decision was based on changes in CSL's internal strategy and was not related to product or service quality.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...